Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 9, Number 5, May 2017, pages 416-425


Role of LncRNA-AF085935, IL-10 and IL-17 in Rheumatoid Arthritis Patients With Chronic Hepatitis C

Figures

Figure 1.
Figure 1. Liver biopsy findings among cases.
Figure 2.
Figure 2. Liver ultrasound findings among cases.
Figure 3.
Figure 3. ROC curve for IL-10 before and after treatment.
Figure 4.
Figure 4. ROC curve for IL-17 before and after treatment.
Figure 5.
Figure 5. ROC curve for lncRNA-AF085935 before and after treatment.

Tables

Table 1. Demographic Characters in Different Study Groups
 
VariablesCases (n = 65), mean ± SDControl (n = 30), mean ± SDP-value
Age (years)39.4 ± 11.741.5 ± 8.40.4
BMI27.6 ± 2.126.1 ± 30.1
Sex, no. (%)
  Male47 (72.3%)19 (63.3%)0.5
  Female18 (27.7%)11 (36.7%)

 

Table 2. Laboratory Investigations in Different Studied Groups
 
VariablesCases (n = 65), mean ± SDControl (n = 30), mean ± SDP-value
AST45.1 ± 14.627.1 ± 7.5< 0.001
ALT52.7 ± 10.626.3 ± 7.8< 0.001
Total bilirubin0.74 ± 0.160.96 ± 0.21< 0.001
Direct bilirubin0.23 ± 0.110.26 ± 0.140.2
Albumin4.1 ± 0.484.3 ± 0.590.06
Alkaline phosphate68.9 ± 24.681.9 ± 28.20.02
PC0.88 ± 0.070.91 ± 0.060.02
INR1.08 ± 0.101.1 ± 0.120.3
Creatinine0.93 ± 0.290.93 ± 0.290.9
HbA1c5.4 ± 0.785.33 ± 0.940.8
TSH1.63 ± 0.981.89 ± 1.50.3
AFP13.2 ± 6.33.33 ± 2.1< 0.001
RBS87.6 ± 23.395.7 ± 26.20.1
Hb (g)13.2 ± 2.310.8 ± 1.1< 0.001
TLC (× 1,000)6.4 ± 1.94.2 ± 1.2< 0.001
Platelets273.6 ± 103.5181.1 ± 69.4< 0.001

 

Table 3. HCV RNA, IL-10, IL-17 and lncRNA-AF085935 in Different Study Groups
 
VariablesG1: before treatment (n = 65), mean ± SDG2: after treatment (n = 65), mean ± SDG3: control (n = 30), mean ± SDP-value
aSignificance between G1 and G2. bSignificance between G1 and G3. cSignificance between G2 and G3.
HCV RNA323,955 ± 337,313.61418,729.7 ± 2,380,203.20.001a
IL-1068.5 ± 24.7201.4 ± 31.951.9 ± 20.3< 0.001a, b, c
IL-17227.9 ± 35.5112.4 ± 28.153.4 ± 20.7< 0.001a, b, c
LncRNA-AF0859354.12 ± 0.674.17 ± 0.661.84 ± 1.11< 0.001b, c

 

Table 4. Correlation Between HCV RNA Level With Other Parameters Before and After Treatment Among Study Group
 
Variablesr (P-value)
HCV-PCR before treatmentHCV-PCR after treatment
IL-100.02 (0.8)0.01 (0.9)
IL-170.05 (0.7)-0.17 (0.2)
LncRNA-AF085935-0.033 (0.9)0.04 (0.8)

 

Table 5. Sensitivity and Specificity of Different Parameters in Predicting the Efficacy of Steroid Therapy in Patients
 
VariableSensitivitySpecificityAccuracyCut-off point
IL-10
  Before77.3%23.3%51%45
  After72.7%30.2%53.9%175.1
IL-17
  Before72.7%25.6%42%198.5
  After81.8%23.3%62.1%196.8
LncRNA-AF085935
  Before63.6%27.2%48.5%3.74
  After68.2%20.9%38.4%3.63